Capricor Therapeutics Announces FDA's Committee Votes That Available Evidence For Deramiocel Did Not Support Effectiveness To Treat Cardiomyopathy In Patients With Duchenne Muscular Dystrophy

Loading news article.

Capricor Therapeutics Announces FDA's Committee Votes That Available Evidence For Deramiocel Did Not Support Effectiveness To Treat Cardiomyopathy In Patients With Duchenne Muscular Dystrophy | WAPE

Capricor Therapeutics Announces FDA's Committee Votes That Available Evidence For Deramiocel Did Not Support Effectiveness To Treat Cardiomyopathy In Patients With Duchenne Muscular Dystrophy

Article summary

Related companies

Comments —